An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Aura Biosciences to Participate at the 11th Annual SVB Leerink Global Healthcare Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology firm, will have CEO Elisabet de los Pinos participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 8:40 a.m. ET. The discussion will be accessible via a live webcast on the company's Investors & Media page, with a replay available for 90 days. Aura is focusing on developing its lead therapy AU-011 for ocular cancers, including a Phase 2 trial for choroidal melanoma.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer of Aura, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare conference taking place on Wednesday, February 16, 2022, at 8:40 a.m. Eastern Time.
A live webcast of the fireside chat will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.
About Aura Biosciences
Aura Biosciences, Inc. (NASDAQ: AURA) is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs), a novel class of therapies, for the treatment of multiple oncology indications. Aura’s lead VDC candidate, AU-011 (belzupacap sarotalocan), consists of a virus-like particle conjugated with an anti-cancer agent. AU-011 selectively targets and destroys cancer cells and activates the immune system with the potential to create long-lasting anti-tumor immunity. AU-011 is currently in development for ocular cancers, with an ongoing Phase 2 clinical trial evaluating first-line treatment of choroidal melanoma, a vision- and life-threatening form of eye cancer where standard of care with radiotherapy leaves patients with severe comorbidities, including major vision loss. Aura plans to develop AU-011 across its ocular oncology franchise including for the treatment of patients with choroidal metastases. In addition, leveraging Aura’s technology platform, Aura is developing AU-011 more broadly across multiple cancers, starting with a planned Phase 1a clinical trial in patients with non-muscle invasive bladder cancer. Aura is headquartered in Cambridge, MA.
Investor and Media Contact:
Matthew DeYoung Argot Partners 212-600-1902 | aura@argotpartners.com
Source: Aura Biosciences, Inc.
FAQ
What is the date and time of Aura Biosciences' fireside chat?
Aura Biosciences (NASDAQ: AURA) will participate in a fireside chat on February 16, 2022, at 8:40 a.m. ET.
Where can I watch the Aura Biosciences fireside chat?
The fireside chat will be available via live webcast on the 'Investors & Media' page of Aura Biosciences' website.
What is the purpose of the fireside chat at the SVB Leerink Global Healthcare Conference?
The fireside chat will feature insights from CEO Elisabet de los Pinos about Aura's development of virus-like drug conjugates for oncology.
What is AU-011, and what is its significance for Aura Biosciences?
AU-011 is Aura's lead drug candidate, aimed at treating ocular cancers by selectively targeting cancer cells and activating the immune system.
What clinical trials is Aura Biosciences currently conducting?
Aura Biosciences is conducting a Phase 2 clinical trial for AU-011 in treating choroidal melanoma and plans a Phase 1a trial for non-muscle invasive bladder cancer.
